<table id="table9" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 9: Proportion of Resistance Analysis Subjects<footnote>Subjects who qualified for resistance analysis.</footnote> with Frequently Emerging Reverse Transcriptase Substitutions from the Pooled Phase 3 TMC278-C209 and TMC278-C215 Trials in the Week 96 Analysis</caption>
<col align="left" valign="top" width="50%"></col>
<col align="center" valign="top" width="25%"></col>
<col align="center" valign="top" width="25%"></col>
<thead>
<tr>
<th stylecode="Lrule Rrule"></th>
<th colspan="2" stylecode="Botrule Rrule">C209 and C215<br/>N = 1368</th>
</tr>
<tr stylecode="Botrule">
<th stylecode="Lrule Rrule"></th>
<th stylecode="Rrule">EDURANT + BR<br/>N = 686</th>
<th stylecode="Rrule">Efavirenz + BR<br/>N = 682</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="3" valign="top">BR = background regimen</td>
</tr>
</tfoot>
<tbody>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Subjects who Qualified for Resistance Analysis</content>
</td>
<td stylecode="Rrule">15% (98/652)</td>
<td stylecode="Rrule">9% (56/604)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Subjects with Evaluable Post-Baseline Resistance Data</content>
</td>
<td stylecode="Rrule">87</td>
<td stylecode="Rrule">43</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">Emerging NNRTI Substitutions</content>
<footnote>V90, L100, K101, K103, V106, V108, E138, V179, Y181, Y188, V189, G190, H221, P225, F227 or M230</footnote>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Any</td>
<td stylecode="Rrule">62% (54/87)</td>
<td stylecode="Rrule">53% (23/43)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">V90I</td>
<td stylecode="Rrule">13% (11/87)</td>
<td stylecode="Rrule">2% (1/43)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">K101E/P/T/Q</td>
<td stylecode="Rrule">20% (17/87)</td>
<td stylecode="Rrule">9% (4/43)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">K103N</td>
<td stylecode="Rrule">1% (1/87)</td>
<td stylecode="Rrule">40% (17/43)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">E138K/A/Q/G</td>
<td stylecode="Rrule">40% (35/87)</td>
<td stylecode="Rrule">2% (1/43)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">  E138K+ M184I<footnote> This combination of NNRTI and NRTI substitutions is a subset of those with the E138K.</footnote>
</td>
<td stylecode="Rrule">25% (22/87)</td>
<td stylecode="Rrule">0</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">V179I/L/D</td>
<td stylecode="Rrule">6% (5/87)</td>
<td stylecode="Rrule">7% (3/43)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Y181C/I/S</td>
<td stylecode="Rrule">10% (9/87)</td>
<td stylecode="Rrule">2% (1/43)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">V189I</td>
<td stylecode="Rrule">8% (7/87)</td>
<td stylecode="Rrule">2% (1/43)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">H221Y</td>
<td stylecode="Rrule">9% (8/87)</td>
<td stylecode="Rrule">0</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">Emerging NRTI Substitutions<footnote>A62V, K65R/N, D67N/G, K70E, L74I, V75I, Y115F, M184I/V, L210F, T215S/T, K219E/R</footnote>
</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Any</td>
<td stylecode="Rrule">57% (50/87)</td>
<td stylecode="Rrule">30% (13/43)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">M184I/V</td>
<td stylecode="Rrule">54% (47/87)</td>
<td stylecode="Rrule">26% (11/43)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">K65R/N</td>
<td stylecode="Rrule">9% (8/87)</td>
<td stylecode="Rrule">5% (2/43)</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">A62V, D67N/G, K70E, Y115F, T215S/T or K219E/R<footnote>These substitutions emerged in addition to the primary substitutions M184V/I or K65R/N; A62V (n=3), D67N/G (n=3), K70E (n=4), Y115F (n=2), T215S/T (n=1), K219E/R (n=8) in rilpivirine resistance analysis subjects.</footnote>
</td>
<td stylecode="Rrule">21% (18/87)</td>
<td stylecode="Rrule">2% (1/43)</td>
</tr>
</tbody>
</table>